Get the Stockscreener App
0.46
6.08%
-0.0298
Gt Biopharma Inc stock is traded at $0.46, with a volume of 769.40K.
It is down -6.08% in the last 24 hours and up +5.41% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$0.4898
Open:
$0.4713
24h Volume:
769.40K
Relative Volume:
0.55
Market Cap:
$16.59M
Revenue:
-
Net Income/Loss:
$-47.73M
P/E Ratio:
-0.0319
EPS:
-14.3996
Net Cash Flow:
$-13.18M
1W Performance:
-6.06%
1M Performance:
+5.41%
6M Performance:
-37.18%
1Y Performance:
-78.80%
1-Day Range:
$0.44
$0.4829
1-Week Range:
$0.44
$0.50
52-Week Range:
$0.261
$2.31
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.49 | 2.97B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.01 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.20 | 349.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
4.72 | 358.07M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.37 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
GT Biopharma (GTBP) Revenue BreakdownMain Composition - Moomoo
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs - The Globe and Mail
GT BIOPHARMA INC (GTBP) Stock Chart - ChartMill
GT Biopharma (GTBP) plans reverse stock split and larger 2022 incentive plan - Stock Titan
Enterprise value to EBITDA forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Morningstar
Enterprise value to EBITDA forward of GT Biopharma Inc – MUN:OXIA - TradingView
Enterprise value to revenue forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to book forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to EBITDA forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to revenue forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to EBIT forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to sales forward of GT Biopharma Inc – FWB:OXIA - TradingView
Price to earnings forward of GT Biopharma Inc – FWB:OXIA - TradingView
GT Biopharma Inc Actuals & Estimates (SWB:OXIA) - TradingView
GT Biopharma Inc (GTBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OXIA Forecast — Price Target — Prediction for 2027 - TradingView
GT Biopharma Inc Actuals & Estimates (NASDAQ:GTBP) - TradingView
GTBP Forecast — Price Target — Prediction for 2027 - TradingView
GT Biopharma Inc (GTBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
GT Biopharma Inc (GTBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GTBP PE Ratio & Valuation, Is GTBP Overvalued - Intellectia AI
GT Biopharma Inc (GTBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GT Biopharma Stocklong-term cancer therapy strategy under review - AD HOC NEWS
GT Biopharma (NASDAQ: GTBP) proposes reverse split and 3.5M share plan increase - Stock Titan
GT Biopharma Inc (GTBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GT Biopharma Inc (GTBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GT Biopharma Inc (GTBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GT Biopharma Inc (GTBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GT Biopharma Inc (GTBP) Institutional Confidence - TradingKey
GTBP Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesPretax Income Report - Město Břeclav
GT Biopharma, Inc. Announces Amendment to Bylaws in June 2026 SEC Form 8-K Filing - Minichart
GTBP Q1 2026 Earnings: Wider-than-Expected Loss but Stock GainsForward EPS Estimate - newsline.com
GT Biopharma Lowers Stockholder Quorum to One-Third - TipRanks
GT Biopharma (NASDAQ: GTBP) lowers meeting quorum to one-third - Stock Titan
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell - GlobeNewswire
GT Biopharma stock (US36254L1098): FDA green light for new TriKE program puts focus on pipeline - AD HOC NEWS
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet - The Manila Times
GT Biopharma, Inc. - MLQ.ai
GTBP Q1 2026 Earnings: EPS Miss Weighs on Sentiment as Biotech Advances PipelineQuarterly Earnings Report - newsline.com
Precision Oncology Platforms Converge as FDA Accelerates Treatment Innovation - Baystreet.ca
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - The Globe and Mail
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - The Manila Times
GT Biopharma Provides Update on Pipeline Discovery - GlobeNewswire
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout - Benzinga
GT Biopharma Inc stock (US36254L1098): Nasdaq micro-cap edges lower ahead of valuation focus - AD HOC NEWS
The $13 Million Company Teaching the Immune System to Hunt Cancer - Quantisnow
SEC Says Former GT Biopharma CEO Used Cancer Research Funds to Buy Beverly Hills Mansion - gritdaily.com
GT Biopharma (GTBP) Maintains Support Zone Amid Modest UptickOption Breadth - newsline.com
GT Biopharma Inc. (GTBP) Falls Over 10% as Biotech Sentiment WeakensADD Alert - The Legal Advocate
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):